Combined treatment with lurbinectedin and irinotecan yields promising early antitumor activity in small-cell lung cancer, with an ORR of 69.2% in 13 evaluable patients.
Pembrolizumab added to first-line therapy with etoposide and platinum chemotherapy for extensive-stage SCLC significantly improved PFS in the final analysis of KEYNOTE-604.
Updated analysis finds durvalumab + EP maintains significant OS improvement vs EP alone with no further benefit with addition of tremelimumab.
At a median follow-up of 80 months, adjuvant gefitinib significantly improved DFS but not OS vs vinorelbine/cisplatin in Chinese patients with completely resected stage IIA-IIIA (N1-N2) EGFR-mutated NSCLC.
Chemotherapy-free treatment with first-line nivolumab and ipilimumab continues to provide durable clinical benefit to patients with advanced NSCLC, regardless of tumor PD-L1 expression.
Nivolumab + ipilimumab + 2 cycles of chemotherapy improved OS vs 4 cycles of chemotherapy alone as first-line therapy for patients with advanced NSCLC.
Dual immune checkpoint inhibition with tiragolumab plus atezolizumab achieved meaningful improvement in ORR and PFS with comparable safety vs placebo plus atezolizumab, with the greatest benefit among patients with PD-L1 TPS ≥ 50%.
T-DXd was associated with a high response rate and durable responses with no new safety signals in previously treated patients with HER2-mutated NSCLC.
Addition of SBRT to first-line EGFR TKI significantly prolonged PFS and OS vs EGFR TKI alone in Chinese patients with EGFR-mutated oligometastatic NSCLC.
Capmatinib was associated with deep responses in both treatment-naive and previously treated patients with NSCLC and high-level MET amplification (GCN ≥ 10).
Pralsetinib associated with a high ORR, intracranial activity, and durable responses in patients with RET fusion–positive NSCLC regardless of prior treatment or RET fusion partner.
Patients who were platinum sensitive during first-line platinum therapy more likely to respond to second-line liposomal irinotecan than those who were platinum resistant.
Adjuvant osimertinib associated with significantly improved disease-free survival after complete resection in patients with stage IB/II/IIIA EGFR-mutated NSCLC.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.